Vir Biotechnology Inc (VIR) showcases progress in oncology and infectious disease programs while managing financial hurdles ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its target price increased by equities researchers at Barclays from ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

Vir stock catapulted by double digits. Please watch the video at Investors.com - How To Buy Stocks: IBD's Four Pillars Of Investing The company's drugs are T-cell engagers. These antibodies ...

Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC ...

$VIR insiders have traded $VIR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales. Here’s a ...

Brent Sabatini, the SVP of $VIR, sold 1,562 shares of the company on 02-13-2025 for an estimated $14,291. We received data on the trade from a recent SEC filing. This ...